Teleflex Inc (TBH.HA)
| Previous close | 195.00 |
| Open | 183.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 183.00 - 183.00 |
| 52-week range | 167.00 - 234.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Teleflex First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Teleflex ( NYSE:TFX ) First Quarter 2024 Results Key Financial Results Revenue: US$737.8m (up 3.8% from 1Q 2023). Net...
GlobeNewswireTeleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. First quarter financial summary Revenues of $737.8 million, up 3.8% compared to the prior year period; up 3.8% on a constant currency basisGAAP diluted EPS from continuing operations of $0.33, compared to $1.63 in the prior year periodAdjusted diluted EPS from continuing operations of $3.21, compared to $3.09 in the prior yea
- GlobeNewswire
Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -Teleflex unveils latest advancements in BPH treatment with UroLift™ 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types - WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Tel
